Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lunesta Has "Encouraging" Debut, Sepracor Says

This article was originally published in The Pink Sheet Daily

Executive Summary

For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.

You may also be interested in...



Ambien CR Gets FDA Approval; Launch Expected In Mid-September

Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.

Ambien CR Gets FDA Approval; Launch Expected In Mid-September

Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.

Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate

Reviewing division's "not approvable" recommendation is overruled by Office Director Temple, FDA review documents show.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel